Market Cap
$10.0B
IBRX
ImmunityBio, Inc.
$10.28 ▲ +10.83%
Prev close $9.28Market cap$10.0B
12-mo target$13.00 (+26.4%)
Insider Selling Cluster (3 insiders)High Impact Filing (8/10)34 New Institutional Positions16 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on IBRX right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Inst. Holders
50 funds
Inst. Value
$1.7B
Inst. Activity
34 buys / 16 sells
Insider Activity
$0.00 buy / $6.9M sell
Insider Net $
-$6.9M
Social Sentiment
61° Warm
SEC Reports
7
Price chart 30d +25.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jan 6, 2027 fda_pdufa
Aug 4, 2026 SEC PDUFA: IBRX — ANKTIVA in BCG-unresponsive NMIBC with papillary disease without CIS — 2027-01-06
FDA target action date 2027-01-06 for IBRX (ImmunityBio, Inc.). Drug: ANKTIVA. Indication: BCG-unres
ImmunityBio reported record Q2 2026 net product revenue of $50.7M, up 92% YoY and 15% sequentially, marking the eighth c
8-K — Impact 5/10
Two directors of ImmunityBio sold a combined ~$2.7M in open-market stock this week, following derivative exercises. The
CLUSTER — Impact 2/10
Two directors at ImmunityBio sold a combined ~$1.06M in open-market sales over a 7-day window, with the largest sale ($8
CLUSTER — Impact 2/10
Jul 2, 2026 Insider
Cohen Cheryl sold 131,210 shares
Director @ $9.50 ($1.2M)
Jul 2, 2026 Insider
Cohen Cheryl acquired via exercise 55,979 shares
Director @ $2.98 ($166.8K)
Jul 1, 2026 Insider
Selecky Christobel acquired via exercise 35,064 shares
Director @ $2.98 ($104.5K)
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
34,083,262 shares ($298.4M)
Analyst ratings buy % -1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 21, 2026 | BTIG | REITERATE | Buy | 53% |
| May 20, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 5, 2026 | D. Boral Capital | MAINTAIN | Buy | 33% |
| Apr 21, 2026 | D. Boral Capital | MAINTAIN | Buy | 33% |
| Apr 8, 2026 | D. Boral Capital | MAINTAIN | Buy | 33% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Aug 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Jul 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Jun 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% |
Price targets
Where 3 covering analysts think IBRX trades over the next 12 months.
$13.00 +26.4% upside Strong Buy
Current$10.29 Low$12.00 Median$12.00 High$15.00 3 analysts
$12.00$15.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood -16.7%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
61°
Warm
BearishNeutralBullish
Recent posts
IBRX has excessively high short positions. A short squeeze could easily occur.
▲ 1 · 💬 0· ⚡ 0.5
What do folks think about SOUN, IBRX, and ONDS?
▲ 1 · 💬 0· ⚡ 0.5
Anyone looking at SOUN, IBRX, or ONDS?
▲ 1 · 💬 0· ⚡ 0.5
Updated Research Report on $HCWB
▲ 1 · 💬 1· ⚡ 0.5
Investment with £5,000…..
▲ 1 · 💬 5· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
7 SEC filing reports analyzed · 3 bullish, 0 bearish, 0 mixed, 4 neutral · avg impact 4.6/10.
NEUTRAL8-K5/10
ImmunityBio reported record Q2 2026 net product revenue of $50.7M, up 92% YoY and 15% sequentially,
Aug 4, 2026
NEUTRALCLUSTER2/10
Two directors of ImmunityBio sold a combined ~$2.7M in open-market stock this week, following deriva
Jul 7, 2026
NEUTRALCLUSTER2/10
Two directors at ImmunityBio sold a combined ~$1.06M in open-market sales over a 7-day window, with
Jul 2, 2026
BULLISH8-K5/10
ImmunityBio entered an exclusive U.S. development and supply agreement with Japan BCG Laboratory for
May 18, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Jan 6, 2027
fda_pdufa
PDUFA: IBRX — ANKTIVA in BCG-unresponsive NMIBC with papillary disease without CIS — 2027-01-06
FDA target action date 2027-01-06 for IBRX (ImmunityBio, Inc.). Drug: ANKTIVA. Indication: BCG-unresponsive NMIBC with papillary disease without CIS.
Oct 1, 2026
short_volume
Short Volume: IBRX — 59.2% short (3.7M / 6.2M)
Short: 3,695,056 | Exempt: 28,194 | TRF Vol: 6,245,701 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: IBRX — 60.5% short (2.3M / 3.8M)
Short: 2,300,987 | Exempt: 4,471 | TRF Vol: 3,806,299 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: IBRX — 65.8% short (1.7M / 2.6M)
Short: 1,704,265 | Exempt: 519 | TRF Vol: 2,589,637 | Short Ratio: 65.8% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: IBRX — 64.2% short (2.6M / 4.0M)
Short: 2,556,604 | Exempt: 5,676 | TRF Vol: 3,985,092 | Short Ratio: 64.2% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.05 | $-0.09–$0.00 | 28.6% | +0.0% | 1↑ 0↓ | $0.1B | 3 |
| Next Q | $-0.04 | $-0.09–$0.00 | 27.8% | +0.0% | 1↑ 0↓ | $0.1B | 3 |
| Current FY | $-0.92 | $-0.93–$-0.90 | -140.8% | +0.0% | 1↑ 1↓ | $0.2B | 2 |
| Next FY | $-0.14 | $-0.35–$0.07 | 84.7% | -10.5% | 1↑ 0↓ | $0.5B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.050 | — |
| 7d ago | $-0.050 | — |
| 30d ago | $-0.050 | — |
| 60d ago | $-0.070 | +0.020 |
| 90d ago | $-0.070 | +0.020 |
Institutional ownership
Which big funds own IBRX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.7B total value (196,142,686 shares) as of 2026-Q2. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 34 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 34,083,262 | $298.4M | 17.4% | ADD +29.4% |
| STATE STREET CORP | 21,398,438 | $187.3M | 10.9% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 17,863,911 | $156.4M | 9.1% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 15,691,579 | $137.4M | 8.0% | — |
| D. E. Shaw & Co., Inc. | 11,551,019 | $101.1M | 5.9% | — |
| TWO SIGMA INVESTMENTS, LP | 11,097,106 | $97.2M | 5.7% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 9,847,896 | $86.2M | 5.0% | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 6,627,600 | $58.1M | 3.4% | NEAR_EXIT -94.4% |
| MILLENNIUM MANAGEMENT LLC | 5,579,793 | $48.9M | 2.8% | DOUBLED +292.9% |
| LMR Partners LLP | 3,983,900 | $34.9M | 2.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 26,346,443 | 34,083,262 | +29.4% | $298.4M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 1,420,244 | 5,579,793 | +292.9% | $48.9M |
| NORTHERN TRUST CORP | ADD | 2,504,781 | 3,565,248 | +42.3% | $31.2M |
| Woodline Partners LP | TRIM | 3,447,346 | 2,500,189 | -27.5% | $21.9M |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | TRIM | 2,927,552 | 1,721,902 | -41.2% | $15.1M |
| Bank of New York Mellon Corp | ADD | 831,430 | 1,314,760 | +58.1% | $11.5M |
| FIRST TRUST ADVISORS LP | NEW | — | 1,214,667 | — | $10.6M |
| OSAIC HOLDINGS, INC. | DOUBLED | 101,316 | 875,621 | +764.2% | $7.7M |
| WELLS FARGO & COMPANY/MN | ADD | 514,721 | 737,031 | +43.2% | $6.5M |
| BARCLAYS PLC | TRIM | 1,890,100 | 730,336 | -61.4% | $6.4M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 45 transactions. Net -$6.9M — $0.00 bought, $6.9M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 2, 2026 | Cohen Cheryl | Director | SELL | 131,210 | $9.50 | $1.2M |
| Jul 2, 2026 | Cohen Cheryl | Director | EXERCISE | 55,979 | $2.98 | $166.8K |
| Jul 1, 2026 | Selecky Christobel | Director | EXERCISE | 35,064 | $2.98 | $104.5K |
| Jul 1, 2026 | Selecky Christobel | Director | SELL | 159,478 | $9.02 | $1.4M |
| Jul 1, 2026 | Selecky Christobel | Director | EXERCISE | 124,414 | $2.99 | $372.0K |
| Jun 30, 2026 | Selecky Christobel | Director | SELL | 1,000 | $9.00 | $9.0K |
| Jun 30, 2026 | Selecky Christobel | Director | EXERCISE | 700 | $2.98 | $2.1K |
| Jun 30, 2026 | Selecky Christobel | Director | EXERCISE | 300 | $2.99 | $897.00 |
| Jun 29, 2026 | Selecky Christobel | Director | EXERCISE | 32,173 | $2.98 | $95.9K |
| Jun 29, 2026 | Selecky Christobel | Director | SELL | 95,722 | $9.01 | $862.2K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for IBRX.
Shares short
125,408,192
Settlement Sep 15, 2026
Change vs prior
-0.2%
Semi-monthly cycle
Days to cover
15.9
At avg daily volume
Of shares outstanding
≈11.8%
Estimate — not % of float
All IBRX filing & press-release reports (7)
- 8-K reportAug 4, 2026
- CLUSTER reportJul 7, 2026
- CLUSTER reportJul 2, 2026
- 8-K reportMay 18, 2026
- 8-K reportApr 9, 2026
- 8-K reportApr 6, 2026
- INST-CLUSTER reportFeb 28, 2026